Exocrine Pancreatic Insufficiency Market: Key Insights
The exocrine pancreatic insufficiency market is growing due to the increasing incidence of chronic pancreatitis and pancreatic cancer, leading to a growing demand for effective treatment options. The market offers several opportunities for growth, such as the development of novel drugs and therapies for exocrine pancreatic insufficiency and increasing awareness about the disease among patients and healthcare providers. In addition, the growing adoption of advanced diagnostic technologies and the growing geriatric population is also anticipated to boost the exocrine pancreatic insufficiency market growth in the coming years. One of the major trends in the exocrine pancreatic insufficiency market is the increasing adoption of enzyme replacement therapy (ERT), which involves replacing the missing pancreatic enzymes with oral supplements. This trend is driven by the increasing recognition of the benefits of ERT, including improved quality of life and better management of symptoms.
However, the high cost of treatment and the limited availability of enzyme replacement therapy in developing countries are some of the major restraints of the market. In addition, the lack of awareness about the disease and the limited availability of specialized healthcare facilities in certain regions are also expected to hinder market growth to some extent.
Rise in the Prevalence of Gastrointestinal Disorders is Driving the Exocrine Pancreatic Insufficiency Market
The rise in the prevalence of gastrointestinal disorders, such as chronic pancreatitis and pancreatic cancer, is driving the exocrine pancreatic insufficiency market. As the number of people affected by these conditions increases, there is a growing demand for effective treatment options for EPI, which is a common complication of these disorders. Chronic pancreatitis is a long-term inflammation of the pancreas that can reduce the production of digestive enzymes, causing EPI. Similarly, pancreatic cancer can also result in EPI, as the tumor or surrounding tissue may obstruct the release of digestive enzymes into the small intestine. As a result, people with these conditions require treatment to manage their symptoms and prevent malnutrition. The increasing prevalence of gastrointestinal disorders drives the demand for EPI treatments, including enzyme replacement therapy (ERT), which replaces the missing digestive enzymes with oral supplements. ERT effectively improves nutrient absorption and alleviates symptoms, making it a valuable treatment option for people with EPI
Exocrine Pancreatic Insufficiency Market: Segmental Overview
The global exocrine pancreatic insufficiency market is segmented on the basis of type and end user. On the basis type segment includes imaging and sample test. The imaging segment is further divided into sub-segments such as CT scanning, endoscopic ultra-sonography (EUS), magnetic resonance imaging (MRI) and others. Similarly, the sample test is further divided into blood test, fecal test, and pancreatic function test. On the basis of the end user the segment is classified as hospitals, diagnostic laboratories, and others.
Fecal tests are expected to hold a substantial share of the market. Fecal tests are non-invasive and simple to perform, making them a popular option for diagnosing EPI. These tests measure the levels of fecal elastase, an enzyme produced by the pancreas, in order to assess pancreatic function. Fecal tests are considered to be highly accurate and reliable, which is why they are widely used to diagnose EPI.
In addition, the growing recognition of the benefits of fecal tests by healthcare providers, combined with the increasing incidence of gastrointestinal disorders that result in EPI, is expected to further drive demand for this diagnostic test in the coming years. As a result, the fecal test segment is expected to continue its upward trajectory and hold a substantial share of the diagnostic test market for exocrine pancreatic insufficiency in the future.
Exocrine Pancreatic Insufficiency Market: Competitive Landscape and Key Developments
Medtronic, General Electric Company, Koninklijke Philips N.V., Siemens Healthcare GmbH, Canon Medical Systems, USA, ThermoFisher Scientific Inc., ScheBo Biotech AG, Hologic Inc., Immunostics, Inc. and Biohit Oyj. are among the key players operating in the exocrine pancreatic insufficiency market. These companies have a widespread presence worldwide, which provides lucrative opportunities to serve a large number of customers and expand the exocrine pancreatic insufficiency market.
Contact Us
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com